Qin Le, Lai Yunxin, Zhao Ruocong, Wei Xinru, Weng Jianyu, Lai Peilong, Li Baiheng, Lin Simiao, Wang Suna, Wu Qiting, Liang Qiubin, Li Yangqiu, Zhang Xuchao, Wu Yilong, Liu Pentao, Yao Yao, Pei Duanqing, Du Xin, Li Peng
Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
J Hematol Oncol. 2017 Mar 13;10(1):68. doi: 10.1186/s13045-017-0437-8.
Multiple iterations of chimeric antigen receptors (CARs) have been developed, mainly focusing on intracellular signaling modules. However, the effect of non-signaling extracellular modules on the expansion and therapeutic efficacy of CARs remains largely undefined.
We generated two versions of CAR vectors, with or without a hinge domain, targeting CD19, mesothelin, PSCA, MUC1, and HER2, respectively. Then, we systematically compared the effect of the hinge domains on the growth kinetics, cytokine production, and cytotoxicity of CAR T cells in vitro and in vivo.
During in vitro culture period, the percentages and absolute numbers of T cells expressing the CARs containing a hinge domain continuously increased, mainly through the promotion of CD4+ CAR T cell expansion, regardless of the single-chain variable fragment (scFv). In vitro migration assay showed that the hinges enhanced CAR T cells migratory capacity. The T cells expressing anti-CD19 CARs with or without a hinge had similar antitumor capacities in vivo, whereas the T cells expressing anti-mesothelin CARs containing a hinge domain showed enhanced antitumor activities.
Hence, our results demonstrate that a hinge contributes to CAR T cell expansion and is capable of increasing the antitumor efficacy of some specific CAR T cells. Our results suggest potential novel strategies in CAR vector design.
嵌合抗原受体(CAR)已历经多次迭代,主要聚焦于细胞内信号传导模块。然而,非信号传导细胞外模块对CAR的扩增及治疗效果的影响在很大程度上仍不明确。
我们分别构建了靶向CD19、间皮素、前列腺干细胞抗原(PSCA)、粘蛋白1(MUC1)和人表皮生长因子受体2(HER2)的两种版本的CAR载体,一种带有铰链区,另一种不带。然后,我们系统地比较了铰链区对体外和体内CAR T细胞的生长动力学、细胞因子产生及细胞毒性的影响。
在体外培养期间,表达含铰链区CAR的T细胞百分比和绝对数量持续增加,主要是通过促进CD4⁺ CAR T细胞的扩增,且与单链可变片段(scFv)无关。体外迁移试验表明,铰链区增强了CAR T细胞的迁移能力。表达含或不含铰链区抗CD19 CAR的T细胞在体内具有相似的抗肿瘤能力,而表达含铰链区抗间皮素CAR的T细胞显示出增强的抗肿瘤活性。
因此,我们的结果表明,铰链区有助于CAR T细胞的扩增,并能够提高某些特定CAR T细胞的抗肿瘤疗效。我们的结果为CAR载体设计提供了潜在的新策略。